NCT06139991View on ClinicalTrials.gov

Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 16, 2023

Primary Completion Date

May 4, 2024

Study Completion Date

May 4, 2024

Conditions
Heathy Participants
Interventions
DRUG

Treatment A (BDA MDI HFO)

Randomized participants will receive Treatment A (BDA MDI HFO) on Day 1 under fasted condition.

DRUG

Treatment B (BDA MDI HFA)

Randomized participants will receive Treatment B (BDA MDI HFA) on Day 1 under fasted condition.

Trial Locations (1)

91206

Research Site, Glendale

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY